IL209666A - Gip-based mixed agonists for treatment of metabolic disorders and obesity - Google Patents

Gip-based mixed agonists for treatment of metabolic disorders and obesity

Info

Publication number
IL209666A
IL209666A IL209666A IL20966610A IL209666A IL 209666 A IL209666 A IL 209666A IL 209666 A IL209666 A IL 209666A IL 20966610 A IL20966610 A IL 20966610A IL 209666 A IL209666 A IL 209666A
Authority
IL
Israel
Prior art keywords
gip
obesity
treatment
metabolic disorders
based mixed
Prior art date
Application number
IL209666A
Other languages
Hebrew (he)
Other versions
IL209666A0 (en
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41570802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL209666(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of IL209666A0 publication Critical patent/IL209666A0/en
Publication of IL209666A publication Critical patent/IL209666A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL209666A 2008-06-17 2010-11-30 Gip-based mixed agonists for treatment of metabolic disorders and obesity IL209666A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7327408P 2008-06-17 2008-06-17
US7817108P 2008-07-03 2008-07-03
US9044808P 2008-08-20 2008-08-20
US15134909P 2009-02-10 2009-02-10
PCT/US2009/047447 WO2010011439A2 (en) 2008-06-17 2009-06-16 Gip-based mixed agonists for treatment of metabolic disorders and obesity

Publications (2)

Publication Number Publication Date
IL209666A0 IL209666A0 (en) 2011-02-28
IL209666A true IL209666A (en) 2015-02-26

Family

ID=41570802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209666A IL209666A (en) 2008-06-17 2010-11-30 Gip-based mixed agonists for treatment of metabolic disorders and obesity

Country Status (27)

Country Link
US (2) US9062124B2 (en)
EP (2) EP2300035B1 (en)
JP (2) JP6108659B2 (en)
KR (1) KR20110040760A (en)
CN (2) CN102105159B (en)
AR (1) AR072159A1 (en)
AU (1) AU2009274425B2 (en)
BR (1) BRPI0915282A2 (en)
CA (1) CA2729296A1 (en)
CL (1) CL2009001425A1 (en)
CO (1) CO6280539A2 (en)
CR (1) CR11849A (en)
DK (1) DK2300035T3 (en)
EA (1) EA020326B9 (en)
EC (1) ECSP10010684A (en)
ES (2) ES2558842T3 (en)
HU (1) HUE028072T2 (en)
IL (1) IL209666A (en)
MA (1) MA32397B1 (en)
MX (1) MX2010013453A (en)
NZ (2) NZ603445A (en)
PE (1) PE20100056A1 (en)
PL (1) PL2300035T3 (en)
SG (1) SG192405A1 (en)
TW (1) TWI474835B (en)
WO (1) WO2010011439A2 (en)
ZA (1) ZA201008807B (en)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP6017754B2 (en) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon / GLP-1 receptor co-agonist
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
EP2249853A4 (en) * 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS BASED ON ESTERS
RU2504373C2 (en) 2008-03-26 2014-01-20 ОРАМЕД Лтд. Methods and compositions for oral administration of proteins
CN105903005A (en) 2008-05-05 2016-08-31 奥拉姆德有限公司 Methods And Compositions For Oral Administration Of Exenatide
JP5753779B2 (en) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analogs with improved solubility and stability in buffers at physiological pH
BRPI0915282A2 (en) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp gip-based mixed agonists for the treatment of metabolic disorders and obesity
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US8992886B2 (en) * 2009-04-06 2015-03-31 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
US9150632B2 (en) * 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
ME02220B (en) 2009-07-13 2016-02-20 Zealand Pharma As Acylated glucagon analogues
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
RU2012136450A (en) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY
AR080592A1 (en) 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
JP5894174B2 (en) 2010-11-03 2016-03-23 アレコー リミテッド Novel composition comprising glucagon
CA2821766A1 (en) * 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
SG191252A1 (en) * 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
KR20140020292A (en) 2011-03-28 2014-02-18 노보 노르디스크 에이/에스 Novel glucagon analogues
DK2694095T3 (en) 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
BR112013032717A2 (en) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp glucagon / glp-1 receptor coagonists
EA031230B1 (en) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon/glp-1 receptor agonists
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
JP6352806B2 (en) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス New glucagon analogues
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN112755002A (en) 2012-02-01 2021-05-07 奥拉姆德有限公司 Compositions containing protease inhibitors, compositions comprising the same, and methods for producing and using the same
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
RU2015101697A (en) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн GLUCAGON ANALOGUES WITH GIP RECEPTOR ACTIVITY
TW201402611A (en) 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp Incretin receptor ligand polypeptide Fc-region fusion polypeptides and conjugates with altered Fc-effector function
JP6300239B2 (en) 2012-06-21 2018-03-28 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analog showing GIP receptor activity
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analog
AR092873A1 (en) 2012-09-26 2015-05-06 Cadila Healthcare Ltd PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
EP2941267B1 (en) * 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP2986314A4 (en) * 2013-03-15 2016-04-13 Univ Indiana Res & Tech Corp PROTOCOLS AND A PROLONGED ACTION
ES2623979T3 (en) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Synthesis of peptide products containing hydantoin
ES2624961T3 (en) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Synthesis of peptide products containing cyclic imide
AR095986A1 (en) 2013-04-03 2015-11-25 Sanofi Sa MODIFIED PROTEINS THAT REGULATE GLUCOSE IN BLOOD WITH ALTERED PROFILE OF PHARMACOLOGICAL ACTIVITY AND PREPARATION OF THE SAME
PL2986313T3 (en) 2013-04-18 2019-12-31 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
LT3004155T (en) 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited PEPTIDE COMPOUND
WO2015022420A1 (en) * 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015035419A1 (en) * 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
SI3057984T1 (en) 2013-10-17 2018-10-30 Zealand Pharma A/S Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10093713B2 (en) * 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EA035688B1 (en) * 2013-11-06 2020-07-27 Зилэнд Фарма А/С Glucagon-glp-1-gip triple agonist compounds
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080151A1 (en) * 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
WO2015086730A1 (en) * 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086731A1 (en) * 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
CA2933701C (en) 2013-12-18 2022-05-31 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR098614A1 (en) 2013-12-18 2016-06-01 Lilly Co Eli COMPOUND FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
WO2015095684A1 (en) 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
AR100306A1 (en) 2014-02-18 2016-09-28 Novo Nordisk As GLUCAGON ANALOGS STABLE AND USE FOR THE TREATMENT OF HYPOGLUCEMIA
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2822994T3 (en) * 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Incretin-insulin conjugates
CN107108715A (en) 2014-10-24 2017-08-29 默沙东公司 The co-agonists of hyperglycemic factor and the acceptors of GLP 1
TWI705973B (en) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Gip agonist compounds and methods
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JP2018012644A (en) * 2014-11-26 2018-01-25 武田薬品工業株式会社 Peptide compound
TN2017000271A1 (en) 2014-12-30 2018-10-19 Hanmi Pharm Ind Co Ltd Glucagon derivative having improved stability
TWI707867B (en) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 Acylated glucagon analogue
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TN2017000555A1 (en) 2015-06-30 2019-04-12 Hanmi Pharm Ind Co Ltd Glucagon derivative and a composition comprising a long acting conjugate of the same
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonist
PH12018501409B1 (en) * 2015-12-31 2023-03-10 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
CN109477094B (en) 2016-05-24 2022-04-26 武田药品工业株式会社 Peptide compounds
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
JP7208020B2 (en) * 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド Glucagon derivatives, conjugates thereof, compositions containing same, and therapeutic uses thereof
CN109200273B (en) * 2017-07-04 2021-02-19 中国药科大学 Application of polypeptide in preparation of medicine for preventing or treating fatty liver disease
AR110301A1 (en) 2016-12-02 2019-03-13 Sanofi Sa COMPOUNDS AS GLP1 / GLUCAGÓN / GIP RECEPTING AGENISTS
AR110300A1 (en) 2016-12-02 2019-03-13 Sanofi Sa COMPOUNDS AS TRIGONAL PEPTIDE AGONISTS OF GLP1 / GLUCAGÓN / GIP RECEPTORS
GB201620611D0 (en) * 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (en) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co Polypeptide compound
AR113486A1 (en) * 2017-12-21 2020-05-06 Lilly Co Eli INCRETINE ANALOGUES AND ITS USES
EA202092269A1 (en) * 2018-03-23 2020-12-14 Кармот Терапьютикс, Инк. G-PROTEIN-COUPLED RECEPTOR MODULATORS
BR112020020647A2 (en) 2018-04-10 2021-02-23 Sanofi-Aventis Deutschland Gmbh synthesis of lixisenatide with capping
KR102793451B1 (en) 2018-04-10 2025-04-11 사노피-아벤티스 도이칠란트 게엠베하 Method for cleaving a solid-phase-bound peptide from a solid phase
TWI707865B (en) 2018-05-04 2020-10-21 丹麥商諾佛 儂迪克股份有限公司 Gip derivatives and uses thereof
TW202015735A (en) 2018-05-30 2020-05-01 法商賽諾菲公司 Conjugate including GLP-1/L-glycoside/GIP triple receptor agonist, linker and hyaluronic acid
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2021083306A1 (en) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg dual-acceptor agonist polypeptide
FI4097099T3 (en) 2020-02-07 2024-07-30 Gasherbrum Bio Inc HETEROCYCLIC GLP-1 AGONISTS
WO2021169512A1 (en) * 2020-02-24 2021-09-02 中山大学 Polypeptide compound and application thereof in prevention or treatment of diabetes or diabetes complication
PL4143183T3 (en) 2020-04-29 2026-03-02 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CA3184717A1 (en) 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonists at glp-1 and gip receptors suitable for oral delivery
WO2022018185A1 (en) 2020-07-22 2022-01-27 Novo Nordisk A/S Glp-1 and gip receptor co-agonists
JP2023550594A (en) * 2020-10-30 2023-12-04 ノヴォ ノルディスク アー／エス GLP-1, GIP, and glucagon receptor triple agonist
CN114617956B (en) * 2020-12-10 2023-10-03 江苏中新医药有限公司 High-efficiency hypoglycemic protein medicine
CN117980325A (en) 2021-05-13 2024-05-03 卡莫特治疗学股份有限公司 Modulators of G-protein coupled receptors
CN117794946A (en) * 2021-06-09 2024-03-29 斯克利普斯研究所 Long-acting dual GIP/GLP-1 peptide conjugates and methods of use
WO2023030444A1 (en) * 2021-09-02 2023-03-09 广东东阳光药业有限公司 Glp-1/gip dual-targeted polypeptide and fusion protein and applications thereof
TW202330584A (en) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 Prodrugs and uses thereof
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
EP4496797A1 (en) 2022-03-21 2025-01-29 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN115490760B (en) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 GLP-1 receptor and GCG receptor co-agonist polypeptide derivative
JP2026501171A (en) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Salts and solid forms of compounds with GLP-1 agonist activity
EP4638440A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN118255864A (en) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 GIP receptor agonists and uses thereof
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
TW202521528A (en) 2023-07-13 2025-06-01 美商雅空嘉閣生物公司 Compounds, compositions, and methods
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025016303A1 (en) * 2023-07-14 2025-01-23 北京拓界生物医药科技有限公司 Glp-1, gip and gcg receptor triagonist and use thereof
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
CN117186206B (en) * 2023-10-20 2024-07-23 广东药科大学 Novel covalent polymer of different GLP1 analogue peptides, and preparation method and application thereof
CN120349392A (en) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 GIP agonist compound
TW202540155A (en) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Tri-agonists of the glp-1, gip, and amylin receptors
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275152A (en) * 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology Method for enhancing glycoprotein stability.
ES2075196T3 (en) * 1989-02-17 1995-10-01 Chiron Mimotopes Pty Ltd METHOD FOR USE AND SYNTHESIS OF PEPTIDES.
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69129226T2 (en) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley GLP-1 ANALOG USES IN DIABETE TREATMENT
CA2024855C (en) 1990-09-07 1997-12-09 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Process and intermediates for producing glucagon
JPH04145099A (en) 1990-10-05 1992-05-19 Sanwa Kagaku Kenkyusho Co Ltd Polypeptide derivative having gip-like activity and use thereof
ATE135372T1 (en) * 1991-01-17 1996-03-15 Zymogenetics Inc METHOD FOR DETECTING GLUCAGON ANTAGONISTS
US5510459A (en) * 1991-01-17 1996-04-23 Zymogenetics, Inc. Glucagon antagonists
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5869602A (en) * 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
JPH0940699A (en) * 1995-07-28 1997-02-10 Sanwa Kagaku Kenkyusho Co Ltd Polypeptide and its use
DE19530865A1 (en) 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
JP2001503963A (en) 1996-02-06 2001-03-27 イーライ・リリー・アンド・カンパニー Diabetes treatment
JP2000516912A (en) 1996-06-05 2000-12-19 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Exendin analogs, methods for their preparation and formulations containing them
NZ334595A (en) 1996-09-09 2000-08-25 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
UA65549C2 (en) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
JP4394279B2 (en) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ Pharmacologically active peptide conjugates with reduced propensity to enzymatic hydrolysis
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
CN1495198A (en) * 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ Analogs of glucagon-like peptide-1
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
US6921748B1 (en) * 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CA2405900A1 (en) 2000-04-27 2001-11-01 Bionebraska, Inc. Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
AU2001269833A1 (en) * 2000-06-14 2001-12-24 Cytovax Biotechnologies, Inc. Use of coiled-coil structural scaffold to generate structure-specific peptides
AU6479101A (en) 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
CN1454214A (en) * 2000-08-02 2003-11-05 赛莱技术公司 Modified Biopeptides with Enhanced Efficacy
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
WO2002026265A2 (en) * 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
US20040002468A1 (en) * 2001-08-08 2004-01-01 Genzyme Corporation Methods of treating diabetes and other blood sugar disorders
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AR036711A1 (en) * 2001-10-05 2004-09-29 Bayer Corp PEPTIDES THAT ACT AS GLON-RECEPTOR AGONISTS AND AS GLUCAGON RECEPTOR ANTAGONISTS AND THEIR PHARMACOLOGICAL USE METHODS
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
US6864069B2 (en) 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
HUP0700151A2 (en) * 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005508360A (en) 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー GLP-1 and insulin biphasic mixture
JP2005518408A (en) * 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Combination use of GLP-1 compounds and other drugs to treat dyslipidemia
MXPA04006679A (en) 2002-01-08 2004-11-10 Lilly Co Eli Extended glucagon-like peptide-1 analogs.
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
EP1575490A4 (en) 2002-06-04 2007-08-08 Lilly Co Eli Modified glucagon-like peptide-1 analogs
WO2003103697A2 (en) 2002-06-11 2003-12-18 Cell Therapeutics Scandinavia Ab Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
US20040029805A1 (en) 2002-06-15 2004-02-12 Wolfe M. Michael Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
CN1750842A (en) * 2003-02-19 2006-03-22 研究及应用科学协会股份有限公司 Analogs of GLP-1
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
EA009366B1 (en) * 2003-03-19 2007-12-28 Эли Лилли Энд Компани Polyethelene glycol link glp-1 compounds
CA2843439A1 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN1822851B (en) 2003-05-15 2011-04-13 塔夫茨大学信托人 Stable analogs of peptide and polypeptide drugs
PL1633390T3 (en) 2003-06-03 2012-06-29 Novo Nordisk As Stabilized pharmaceutical glp-1 peptide compositions
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
EA008831B1 (en) * 2003-06-12 2007-08-31 Эли Лилли Энд Компани SLIP PROTEINS OF GLP-1 ANALOGUES
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US7364875B2 (en) * 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
AU2004298424A1 (en) * 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US8527752B2 (en) 2004-06-16 2013-09-03 Dormarke Assets Limited Liability Graduated authentication in an identity management system
JP4666342B2 (en) 2004-07-26 2011-04-06 ルネサスエレクトロニクス株式会社 Semiconductor integrated circuit device
US20080305986A1 (en) * 2004-08-16 2008-12-11 Killian Waldemar Conde Fieboes Multimers of Peptides
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
EP1863537A2 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
WO2006121904A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
KR101011081B1 (en) 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Pylated PL-1 Compound
DK1891105T3 (en) 2005-06-13 2012-07-16 Imp Innovations Ltd New compounds and their effects on eating behavior
US7360772B2 (en) 2005-07-20 2008-04-22 Koch Hal D Child transport air filtering system
EP1943274A2 (en) 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
US20090286722A1 (en) 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
US8338368B2 (en) * 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
ES2397659T3 (en) * 2006-03-15 2013-03-08 Novo Nordisk A/S Mixtures of amylin and insulin
CN101432025B (en) 2006-03-21 2012-04-04 安米林药品公司 Peptide-peptidase inhibitor conjugates and methods of use
MX2008013304A (en) 2006-04-20 2008-10-27 Amgen Inc Glp-1 compounds.
WO2008022015A2 (en) 2006-08-11 2008-02-21 Trustees Of Tufts College Retro-inverso incretin analogues, and methods of use thereof
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US20080053857A1 (en) 2006-08-31 2008-03-06 Paul Vincent Enriquez Albano Package having two different views for increased awareness in display
DK2615108T3 (en) * 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
EP2102355B1 (en) 2006-12-14 2016-03-02 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
JP6017754B2 (en) * 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon / GLP-1 receptor co-agonist
DK2158214T3 (en) * 2007-06-15 2011-12-05 Zealand Pharma As Glucagon analogues
US7859468B2 (en) * 2007-08-30 2010-12-28 Research In Motion Limited Mobile wireless communications device including a folded monopole multi-band antenna and related methods
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
ES2672770T3 (en) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivatives of glucagon-like peptide-1 and its pharmaceutical use
EP2200626A4 (en) 2007-09-07 2012-02-15 Ipsen Pharma Sas Analogues of exendin-4 and exendin-3
CN101854948A (en) 2007-09-11 2010-10-06 诺沃-诺迪斯克有限公司 Combination containing amylin and long-acting insulin
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
CN101918027A (en) 2007-11-02 2010-12-15 森托科尔奥索生物科技公司 Semi-synthetic GLP-1 peptide-Fc fusion structure, method and use thereof
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS BASED ON ESTERS
CN101980725B (en) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 Prodrug comprising a drug linker conjugate
AU2009260302B2 (en) * 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (en) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analogs with improved solubility and stability in buffers at physiological pH
BRPI0915282A2 (en) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp gip-based mixed agonists for the treatment of metabolic disorders and obesity
KR20110114568A (en) 2008-12-19 2011-10-19 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Dipeptide linked medicinal agents
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
RU2012136450A (en) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн CONJUGATES GLUCAGON ANTAGONIST - GIP AGONIST AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY
AR080592A1 (en) 2010-03-26 2012-04-18 Lilly Co Eli PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS
WO2011163473A1 (en) 2010-06-25 2011-12-29 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers

Also Published As

Publication number Publication date
US20150322130A1 (en) 2015-11-12
IL209666A0 (en) 2011-02-28
CN102105159B (en) 2015-07-08
WO2010011439A3 (en) 2010-05-14
US20110166062A1 (en) 2011-07-07
ZA201008807B (en) 2011-09-28
TW201010729A (en) 2010-03-16
SG192405A1 (en) 2013-08-30
CA2729296A1 (en) 2010-01-28
DK2300035T3 (en) 2015-11-16
AU2009274425A1 (en) 2010-01-28
AU2009274425B2 (en) 2014-05-15
BRPI0915282A2 (en) 2017-02-07
NZ603445A (en) 2014-03-28
AR072159A1 (en) 2010-08-11
JP2015164922A (en) 2015-09-17
EA020326B9 (en) 2015-03-31
ECSP10010684A (en) 2011-01-31
ES2558842T3 (en) 2016-02-09
CN104945500B (en) 2019-07-09
US9062124B2 (en) 2015-06-23
PE20100056A1 (en) 2010-01-26
CR11849A (en) 2011-07-18
EP2300035B1 (en) 2015-08-12
CL2009001425A1 (en) 2010-04-30
EP2300035A4 (en) 2011-08-31
PL2300035T3 (en) 2016-04-29
EP2300035A2 (en) 2011-03-30
CN102105159A (en) 2011-06-22
HUE028072T2 (en) 2016-11-28
MX2010013453A (en) 2011-01-21
ES2650038T3 (en) 2018-01-16
CN104945500A (en) 2015-09-30
CO6280539A2 (en) 2011-05-20
KR20110040760A (en) 2011-04-20
HK1153934A1 (en) 2012-04-13
EA020326B1 (en) 2014-10-30
EA201001801A1 (en) 2011-08-30
JP6108659B2 (en) 2017-04-05
EP2952202A1 (en) 2015-12-09
MA32397B1 (en) 2011-06-01
EP2952202B1 (en) 2017-10-18
JP2011524420A (en) 2011-09-01
NZ589848A (en) 2012-11-30
WO2010011439A2 (en) 2010-01-28
TWI474835B (en) 2015-03-01
JP6174071B2 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
ZA201008807B (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
IL258730A (en) Compositions and methods for treatment of microbial disorders
EP2405755A4 (en) Methods and compositions for the treatment of metabolic and cardiovascular disorders
IL209032A0 (en) Compositions and methods for treating digestive disorders
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
EP2424464A4 (en) Devices and methods for treating gastrointestinal and metabolic disorders
IL194189A0 (en) Combination treatment of metabolic disorders
ZA201008952B (en) Compositions and methods of use for therapeutic antibodies
ZA201007127B (en) Carboxamide compounds for the treatment of metabolic disorders
EP2293800A4 (en) Compositions and methods for treatment of ear disorders
EP2637667A4 (en) Ibat inhibitors for treatment of metabolic disorders and related conditions
EP2205236A4 (en) Novel agents for treatment of ailments and dysfunctions
GB2552405B (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
EP2051732A4 (en) Methods of diagnosis and treatment for metabolic disorders
SG10201501316VA (en) Compositions and methods for treatment of kidney disorders
ZA200904281B (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2010085811A9 (en) Use of pterosin compounds for treating diabetes and obesity
EP2147715A4 (en) Structure of in-line mixer
EP2147013A4 (en) Methods and compositions for diagnosis and treatment of depression and anxiety
EP2431041A4 (en) Pharmaceutical composition for treating cardiovascular disorder and use thereof
PT2227246E (en) Treatment of fibroses and liver disorders
IL210558A0 (en) Treatment of anxiety disorders
EP2480099A4 (en) Compositions and methods for the prevention and treatment of metabolic diseases
EP2240024A4 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees